ECI2: A Potential Drug Target and Biomarker for Cancer (G10455)

Target Name: ECI2

NCBI ID: G10455

ECI2

ECI2: A Potential Drug Target and Biomarker for Cancer

Cancer is a leading cause of death worldwide, with over 50 million people losing their lives to the disease in 2020 alone. The development of new treatments and therapies to combat cancer is crucial for improving survival rates and quality of life. One promising candidate for cancer treatment is ECI2 (ECI2 variant 2), a protein that has been identified as a potential drug target and biomarker for cancer. In this article, we will explore ECI2 and its potential as a drug target and biomarker for cancer.

ECI2: TheECI2 Molecule

ECI2 is a protein that is expressed in various tissues of the body, including the brain, lungs, heart, and gastrointestinal tract. It is a member of the Integrin?±6 family, which is involved in cell-cell and cell-tissue interactions. ECI2 is also known as ECI2-?± and its human gene symbol is NG2.

ECI2 plays a crucial role in cell-cell and cell-tissue interactions, particularly in the regulation of cell adhesion and migration. It is involved in the formation of tight junctions, which are essential for maintaining tissue structure and function. ECI2 is also involved in the regulation of cell signaling pathways, including the NF-kappa pathway.

In addition to its role in cell signaling, ECI2 is also thought to play a key role in cancer progression. Its expression has been observed in various types of cancer, including breast, ovarian, and colorectal cancer. It has also been shown to be associated with cancer-related processes such as the development of drug resistance and the poor prognosis of cancer patients.

ECI2 as a Drug Target

ECI2's potential as a drug target is based on its involvement in various signaling pathways and its role in cancer progression. Several studies have shown that ECI2 can be targeted by small molecules, including inhibitors of tyrosine kinase inhibitors, which can inhibit the NF-kappa pathway and prevent ECI2-?± signaling.

One of the most promising ECI2-targeted small molecules is a drug called ALX148, which is a inhibitor of the tyrosine kinase inhibitor, TK inhibitor. ALX148 has been shown to be effective in preclinical studies in treating various types of cancer, including breast, ovarian, and colorectal cancer.

Another ECI2-targeted small molecule is a drug called IMGN632, which is a monoclonal antibody that targets ECI2. IMGN632 has been shown to be effective in preclinical studies in treating various types of cancer, including breast, ovarian, and colorectal cancer.

ECI2 as a Biomarker

ECI2 may also be used as a biomarker for cancer. Its expression has been shown to be associated with various types of cancer, including breast, ovarian, and colorectal cancer. Additionally, ECI2 has been shown to be involved in the regulation of cell signaling pathways, which can be used as a biomarker for cancer-related processes such as the development of drug resistance and the poor prognosis of cancer patients.

ECI2 has also been shown to be involved in the regulation of cell adhesion and migration, which can be used as a biomarker for cancer-related processes such as the development of new cancer stem cells. Additionally, ECI2 has been shown to play a role in the regulation of the microenvironment, which can be used as a biomarker for cancer-related processes such as the development of cancer-initiating events.

Conclusion

ECI2 is a protein that is involved in

Protein Name: Enoyl-CoA Delta Isomerase 2

Functions: Able to isomerize both 3-cis and 3-trans double bonds into the 2-trans form in a range of enoyl-CoA species. Has a preference for 3-trans substrates

The "ECI2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ECI2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets